New Clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses

PharmacoEconomics

Volumn 30, Issue 10, 2012, Pages 869-885

  Mapel, Douglas W ^a   Roberts, Melissa H ^a  

^a LOVELACE CLINIC FOUNDATION   (United States)

Author keywords

chronic obstructive pulmonary disease; cost effectiveness; healthcare expenditure; modelling; pharmacoeconomics.

Indexed keywords

ANTIINFECTIVE AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; FORMOTEROL; INDICATEROL; IPRATROPIUM BROMIDE; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; AIRWAY OBSTRUCTION; ANGINA PECTORIS; ARTICLE; BRONCHITIS; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISABILITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPEPSIA; ECONOMIC EVALUATION; EMERGENCY WARD; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HEART ARRHYTHMIA; HOSPITAL ADMISSION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LONG TERM CARE; LUNG FUNCTION; OUTCOME ASSESSMENT; PHARMACOECONOMICS; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPIROMETRY; STOMACH ULCER; STRUCTURED INTERVIEW; UNITED STATES;

COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; DRUG DESIGN; ECONOMICS, PHARMACEUTICAL; HUMANS; MARKOV CHAINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

EID: 84866116850     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11633330-000000000-00000     Document Type: Article

References (139)

1. National Heart, Lung, and Blood Institute. Morbidity & mortality: 2009 chart book on cardiovascular, lung, and blood diseases [online]. Available from URL: http://www. nhlbi.nih.gov/resources/docs/2009-ChartBook.pdf [Accessed 2012 Jan 5]
2. Van Wave TW, Scutchfield FD, Honore PA. Recent advances in public health systems research in the United States. Annual review of public health, vol. 31. Palo Alto (CA): Annual Reviews, 2010: 283-95
3. CDC. Deaths from chronic obstructive pulmonary disease: United States, 2000-2005. MMWR Morb Mortal Wkly Rep 2008 Nov 14; 57 (45): 1229-32
4. Mannino DM, Homa DM, Ford ES, et al. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000. MMWR Surveill Summ 2002 Aug 2; 51 (6): 1-16
5. Trupin L, Earnest G, San Pedro M, et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003 Sep; 22 (3): 462-9 (Pubitemid 37098927)
6. Eisner MD, Yelin EH, Trupin L, et al. The influence of chronic respiratory conditions on health status and work disability. Am J Public Health 2002 Sep; 92 (9): 1506-13 (Pubitemid 34921070)
7. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA 1989 Aug 18; 262 (7): 907-13 (Pubitemid 19208947)
8. Blanc PD, Menezes AM, Plana E, et al. Occupational exposures and COPD: an ecological analysis of international data. Eur Respir J 2009 Feb; 33 (2): 298-304
9. Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003 Mar; 97 Suppl. C: S3-14 (Pubitemid 36266865)
10. Machlin S, Chowdhury S. Expenses and characteristics of physician visits in different ambulatory care settings, 2008. MEPS Statistical Brief #318,March 2011 [online]. Available from URL: http://www.meps.ahrq.gov/mepsweb/data-files/ publications/st318/stat318.pdf [Accessed 2012 Jan 5]
11. Soni A. Top 10 most costly conditions among men and women, 2008: estimates for the U.S. civilian noninstitutionalized adult population, age 18 and older. MEPS Statistical Brief #331, July 2011 [online]. Available from URL: http://www.meps.ahrq.gov/mepsweb/data-files/publications/st331/stat331.shtml [Accessed 2012 Jan 5]
12. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD, 2011 [online]. Available from URL: http://www.goldcopd.org/guidelines-global-strategyfor- diagnosis-management.html [Accessed 2012 Jan 5]
13. Molken MP, Van Doorslaer EK, Rutten FF. Economic appraisal of asthma and COPD care: a literature review 1980-1991. Soc Sci Med 1992 Jul; 35 (2): 161-75
14. Ruchlin HS, Dasbach EJ. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19 (6): 623-42 (Pubitemid 32531837)
15. Ramsey SD. Suboptimal medical therapy in COPD: exploring the causes and consequences. Chest 2000 Feb; 117 (2 Suppl.): 33S-7S (Pubitemid 30111562)
16. Ramsey SD, Sullivan SD. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl 2003 Jun; 41: 29s-35s (Pubitemid 36648152)
17. D'Souza AO, Smith MJ, Miller LA, et al. An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. Chest 2006 Jun; 129 (6): 1693-708 (Pubitemid 43895002)
18. Critical assessment of economic evaluation. In:Drummond M, O'Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. New York: Oxford University Press, 1997: 27-51
19. Rutten-Van Molken M, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006 Sep; 3 (7): 630-4 (Pubitemid 44411632)
20. Starkie HJ, Briggs AH, Chambers MG. Pharmacoeconomics in COPD: lessons for the future. Int J Chron Obstruct Pulmon Dis 2008; 3 (1): 71-88 (Pubitemid 351523719)
21. Ferdinands JM, Mannino DM. Obstructive lung disease models: what is valid? COPD 2008 Dec; 5 (6): 382-93
22. Borg S, Ericsson A, Wedzicha J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004 Mar-Apr; 7 (2): 153-67 (Pubitemid 38420728)
23. Hoogendoorn M, Rutten-Van Molken MP, Hoogenveen RT, et al. A dynamic population model of disease progression in COPD. Eur Respir J 2005 Aug; 26 (2): 223-33 (Pubitemid 41079065)
24. Oostenbrink JB, Rutten-Van Molken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005 Jan-Feb; 8 (1): 32-46 (Pubitemid 40293639)
25. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004 Mar 1; 116 (5): 325-31 (Pubitemid 38230292)
26. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23 (6): 619-37 (Pubitemid 40994129)
27. Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005 Sep-Oct; 8 (5): 521-33 (Pubitemid 41727304)
28. McGhan WF, Al M, Doshi JA, et al. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. Value Health 2009 Nov-Dec; 12 (8): 1086-99
29. van der Palen J, Monninkhof E, van der Valk P, et al. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease. Thorax 2006 Jan; 61 (1): 29-33 (Pubitemid 43106974)
30. Lee KH, Phua J, Lim TK. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore. Respir Med 2006 Dec; 100 (12): 2190-6 (Pubitemid 44718390)
31. Dal NR, Eandi M, Pradelli L, et al. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients. Int J Chron Obstruct Pulmon Dis 2007; 2 (2): 169-76 (Pubitemid 47202217)
32. Rutten-Van Molken MP, Oostenbrink JB, Miravitlles M, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007 Jun; 8 (2): 123-35 (Pubitemid 46742896)
33. Bartolomeo N, Trerotoli P, Moretti A, et al. A Markov model to evaluate hospital readmission. BMC Med Res Methodol 2008; 8: 23
34. Chuck A, Jacobs P, Mayers I, et al. Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease. Can Respir J 2008 Nov-Dec; 15 (8): 437-43
35. Earnshaw SR, Wilson MR, Dalal AA, et al. Costeffectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med 2009 Jan; 103 (1): 12-21
36. Nielsen R, Johannessen A, Benediktsdottir B, et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study. Eur Respir J 2009 Oct; 34 (4): 850-7
37. Oba Y. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am J Manag Care 2009 Apr; 15 (4): 226-32
38. Gani R, Griffin J,Kelly S, et al. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim Care Respir J 2010 Mar; 19 (1): 68-74
39. Mapel DW, Schum M, Lydick E, et al. A new method for examining the cost savings of reducing COPD exacerbations. Pharmacoeconomics 2010; 28 (9): 733-49
40. Neyt M, Devriese S, Thiry N, et al. Tiotropium's costeffectiveness for the treatment of COPD: A cost-utility analysis under real-world conditions. BMC Pulm Med 2010; 10: 47
41. Hoogendoorn M, Rutten-Van Molken MP, Hoogenveen RT, et al. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health 2011 Dec; 14 (8): 1039-47
42. Price D, Gray A, Gale R, et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med 2011 Nov; 105 (11): 1635-47
43. Zaniolo O, Iannazzo S, Pradelli L, et al. Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. Eur J Health Econ 2012 Feb; 13 (1): 71-80
44. Foster TS, Miller JD, Marton JP, et al. Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature. COPD 2006 Dec; 3 (4): 211-8 (Pubitemid 44949061)
45. Centers for Disease Control and Prevention (CDC). Prevalence and most common causes of disability among adults: United States, 2005. MMWR Morb Mortal Wkly Rep 2009 May 1; 58 (16): 421-6
46. Centers for Disease Control and Prevention (CDC). Smoking-attributable mortality, years of potential life lost, and productivity losses: United States, 2000-2004. MMWR Morb Mortal Wkly Rep 2008 Nov 14; 57 (45): 1226-8
47. Tinkelman D, Nordyke RJ, Isonaka S, et al. The impact of chronic obstructive pulmonary disease on long-term disability costs. J Manag Care Pharm 2005 Jan-Feb; 11 (1): 25-32
48. Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl. C: S81-9 (Pubitemid 36266873)
49. Chapman KR, Bourbeau J, Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl. C: S23-31 (Pubitemid 36266867)
50. Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl. C: S71-9 (Pubitemid 36266872)
51. Izquierdo JL. The burden of COPD in Spain: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl. C: S61-9 (Pubitemid 36266871)
52. Wouters EF. The burden of COPD in the Netherlands: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl. C: S51-9 (Pubitemid 36266870)
53. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl. C: S43-50 (Pubitemid 36266869)
54. Piperno D, Huchon G, Pribil C, et al. The burden of COPD in France: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl. C: S33-42 (Pubitemid 36266868)
55. Jansson SA, Andersson F, Borg S, et al. Costs of COPD in Sweden according to disease severity. Chest 2002 Dec; 122 (6): 1994-2002 (Pubitemid 36051135)
56. Dal Negro RW, Tognella S, Tosatto R, et al. Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (Social Impact of Respiratory Integrated Outcomes). Respir Med 2008 Jan; 102 (1): 92-101 (Pubitemid 350161843)
57. Fletcher MJ, Upton J, Taylor-Fishwick J, et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health 2011; 11: 612
58. Ayres JG, Price MJ, Efthimiou J. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial. Respir Med 2003 Mar; 97 (3): 212-20 (Pubitemid 36266876)
59. van den Boom G, Rutten-Van Molken MP, Molema J, et al. The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease: results of the DIMCA program. Am J Respir Crit Care Med 2001 Dec 1; 164 (11): 2057-66 (Pubitemid 34023581)
60. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59
61. Morice AH, Celli B, Kesten S, et al. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med 2010 Nov; 104 (11): 1659-67
62. Mannino DM, Gagnon RC, Petty TL, et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000 Jun 12; 160 (11): 1683-9 (Pubitemid 30367908)
63. Mapel DW, Robinson SB, Dastani HB, et al. The direct medical costs of undiagnosed chronic obstructive pulmonary disease. Value Health 2008 Jul-Aug; 11 (4): 628-36 (Pubitemid 352032816)
64. Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in chronic obstructive pulmonary disease: a casecontrol study in a health maintenance organization. Arch Intern Med 2000 Sep 25; 160 (17): 2653-8
65. Dalal AA, Shah M, D'Souza AO, et al. Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med 2011 Mar; 105 (3): 454-60
66. Halpin DM. Health economics of chronic obstructive pulmonary disease. ProcAmThorac Soc 2006May; 3 (3): 227-33 (Pubitemid 43668186)
67. Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010 May; 137 (5): 1091-7
68. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000 May; 161 (5): 1608-13 (Pubitemid 30329036)
69. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Resp J Suppl 2003 Jun; 41: 46s-53s (Pubitemid 36648154)
70. Effing TW, Kerstjens HA, Monninkhof EM, et al. Definitions of exacerbations: does it really matter in clinical trials on COPD? Chest 2009 Sep; 136 (3): 918-23
71. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000 May; 117 (5 Suppl. 2): 398S-401S (Pubitemid 30314474)
72. Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixedtreatment comparison meta-analysis. Pharmacotherapy 2009 Aug; 29 (8): 891-905
73. Mapel DW, Hurley JS, Dalal AA, et al. The role of combination inhaled corticosteroid/long-acting beta-agonist therapy in COPD management. Prim Care Respir J 2010 Jun; 19 (2): 93-103
74. Naik S, Kamal KM, Keys PA, et al. Evaluating the costeffectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease. Clinicoecon Outcomes Res 2010; 2: 25-36
75. Mittmann N, Hernandez P, Mellstrom C, et al. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives. Pharmacoeconomics 2011 May; 29 (5): 403-14
76. Aaron SD, Ramsay T, Vandemheen K, et al. A threshold regression model for recurrent exacerbations in chronic obstructive pulmonary disease. J Clin Epidemiol 2010 Dec; 63 (12): 1324-31
77. Workshop report: 2005 update. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease [online]. Available from URL: http://goldcopd.org/guidelines-global-strategy-for-diagnosis-man agement.html [Accessed 2012 Jan 5]
78. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008 Apr; 31 (4): 869-73
79. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010 Sep; 363 (12): 1128-38
80. Balcells E, Anto JM, Gea J, et al. Characteristics of patients admitted for the first time for COPD exacerbation. Respir Med 2009 Sep; 103 (9): 1293-302
81. Rutten-Van Molken MP, Hoogendoorn M, Lamers LM. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics 2009; 27 (6): 465-77
82. Kaplan RM, Atkins CJ, Timms R. Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease. J Chronic Dis 1984; 37 (2): 85-95 (Pubitemid 14221380)
83. Benzo RP, Chang CC, Farrell MH, et al. Physical activity, health status and risk of hospitalization in patients with severe chronic obstructive pulmonary disease. Respiration 2010; 80 (1): 10-8
84. Moy ML, Reilly JJ, Ries AL, et al. Multivariate models of determinants of health-related quality of life in severe chronic obstructive pulmonary disease. J Rehabil Res Dev 2009; 46 (5): 643-54
85. Kaplan RM. The minimally clinically important difference in generic utility-based measures. COPD 2005 Mar; 2 (1): 91-7 (Pubitemid 40776228)
86. Kaplan RM, Ries AL, Reilly J, et al. Measurement of health-related quality of life in the National Emphysema Treatment Trial. Chest 2004 Sep; 126 (3): 781-9 (Pubitemid 39258032)
87. Martinez FJ, Foster G, Curtis JL, et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 2006 Jun 15; 173 (12): 1326-34 (Pubitemid 43900706)
88. Ramsey SD, Berry K, Etzioni R, et al. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl JMed 2003 May 22; 348 (21): 2092-102 (Pubitemid 36583305)
89. Hays RD, Kim S, Spritzer KL, et al. Effects of mode and order of administration on generic health-related quality of life scores. Value Health 2009 Sep; 12 (6): 1035-9
90. Fryback DG, Dunham NC, Palta M, et al. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care 2007 Dec; 45 (12): 1162-70
91. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005 Mar; 43 (3): 203-20 (Pubitemid 40353904)
92. Naberan K, Azpeitia A, Cantoni J, et al. Impairment of quality of life in women with chronic obstructive pulmonary disease. Respir Med 2012; 106 (3): 367-73
93. Miravitlles M, Naberan K, Cantoni J, et al. Socioeconomic status and health-related quality of life of patients with chronic obstructive pulmonary disease. Respiration 2011; 82 (5): 402-8
94. Miravitlles M, Llor C, de Castellar R, et al. Validation of the COPD severity score for use in primary care: the NEREA study. Eur Respir J 2009 Mar; 33 (3): 519-27
95. Rutten-Van Molken MP, Oostenbrink JB, Tashkin DP, et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006 Oct; 130 (4): 1117-28 (Pubitemid 44583743)
96. Stahl E, Jansson SA, Jonsson AC, et al. Health-related quality of life, utility, and productivity outcomes instruments: ease of completion by subjects with COPD. Health Qual Life Outcomes 2003; 1: 18
97. Goossens LM, Nivens MC, Sachs P, et al. Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? Respir Med 2011 Aug; 105 (8): 1195-202
98. Garcia-Rio F, Soriano JB, Miravitlles M, et al. Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life. Chest 2011 May; 139 (5): 1072-80
99. Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 2003 Apr; 56 (4): 317-25 (Pubitemid 36593310)
100. Ringbaek T, Brondum E, Martinez G, et al. EuroQoL in assessment of the effect of pulmonary rehabilitation COPD patients. Respir Med 2008 Nov; 102 (11): 1563-7
101. Briggs AH, Glick HA, Lozano-Ortega G, et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J 2010 Mar; 35 (3): 532-9
102. Lock K, Wilson K, Murphy D, et al. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother 2011 Dec; 12 (17): 2613-26
103. Sun SX, Marynchenko M, Banerjee R, et al. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. J Med Econ 2011; 14 (6): 805-15
104. Zaniolo O, Iannazzo S, Pradelli L, et al. Pharmacoeconomic evaluation of tiotropium bromide in the longterm treatment of chronic obstructive pulmonary disease (COPD) in Italy. Eur J Health Econ 2012; 13 (1): 71-80
105. Mapel DW, Picchi MA, Hurley JS, et al. Utilization in COPD: patient characteristics and diagnostic evaluation. Chest 2000 May; 117 (5 Suppl. 2): 346S-53S (Pubitemid 30314465)
106. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD 2005 Mar; 2 (1): 35-41 (Pubitemid 40776220)
107. Lindberg A, Larsson LG, Ronmark E, et al. Co-morbidity in mild-to-moderate COPD: comparison to normal and restrictive lung function. COPD 2011 Dec; 8 (6): 421-8
108. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005 Feb 15; 142 (4): 233-9 (Pubitemid 40216240)
109. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 Feb 22; 356 (8): 775-89 (Pubitemid 46294610)
110. Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010 Aug; 65 (8): 719-25
111. Jadad AR, To MJ, Emara M, et al. Consideration of multiple chronic diseases in randomized controlled trials. JAMA 2011; 306 (24): 2670-2
112. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010 Jan; 137 (1): 20-30
113. Donohue JF, Singh D, Kornmann O, et al. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011; 6: 477-92
114. Worth H, Chung KF, Felser JM, et al. Cardio-and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011 Apr; 105 (4): 571-9
115. McGarvey LP, Magder S, Burkhart D, et al. Cause-specific mortality adjudication in the UPLIFTCOPD trial: findings and recommendations. Respir Med 2012; 106 (4): 515-21
116. McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007 May; 62 (5): 411-5 (Pubitemid 46698390)
117. Lin PJ, Shaya FT, Scharf SM. Economic implications of comorbid conditions among Medicaid beneficiaries with COPD. Respir Med 2010 May; 104 (5): 697-704
118. Menzin J, Boulanger L, Marton J, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med 2008 Sep; 102 (9): 1248-56
119. Mapel DW, McMillan GP, Frost FJ, et al. Predicting the costs of managing patients with chronic obstructive pulmonary disease. Respir Med 2005 Oct; 99 (10): 1325-33 (Pubitemid 41245321)
120. Dalal AA, Shah M, Lunacsek O, et al. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Med 2011 Oct; 105 (10): 1516-22
121. Patel AR, Donaldson GC, Mackay AJ, et al. The impact of ischemic heart disease on symptoms, health status and exacerbations in COPD. Chest 2012 Apr; 141 (4): 851-7
122. Akazawa M, Halpern R, Riedel AA, et al. Economic burden prior to COPD diagnosis: a matched case-control study in the United States. Respir Med 2008 Dec; 102 (12): 1744-52
123. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977 Jun 25; 1 (6077): 1645-8 (Pubitemid 8124466)
124. Agusti A, Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011 Sep 1; 184 (5): 507-13
125. Kohansal R, Martinez-Camblor P, Agusti A, et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009 Jul 1; 180 (1): 3-10
126. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Respir Crit Care Med 2001 Aug 1; 164 (3): 358-64 (Pubitemid 32778199)
127. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002 Oct; 57 (10): 847-52 (Pubitemid 35178607)
128. Kerstjens HA, Rijcken B, Schouten JP, et al. Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax 1997 Sep; 52 (9): 820-7 (Pubitemid 27412566)
129. Silverman EK. Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression? Proc Am Thorac Soc 2007 Dec; 4 (8): 586-90 (Pubitemid 350291618)
130. Celli BR. Predictors of mortality in COPD. Respir Med 2010 Jun; 104 (6): 773-9
131. Cooper K, Brailsford SC, Davies R. Choice of modelling technique for evaluating health care interventions. J Oper Res Soc 2007 Feb; 58 (2): 168-76 (Pubitemid 46224660)
132. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006 Dec; 15 (12): 1295-310 (Pubitemid 44941606)
133. Caro JJ, Moller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations? Value Health 2010 Dec; 13 (8): 1056-60
134. Pichon-Riviere A, Augustovski F, Bardach A, et al. Development and validation of a microsimulation economic model to evaluate the disease burden associated with smoking and the cost-effectiveness of tobacco control interventions in Latin America. Value Health 2011 Jul-Aug; 14 (5 Suppl. 1): S51-9
135. Mullahy J. Econometric modeling of health care costs and expenditures: a survey of analytical issues and related policy considerations. Med Care 2009 Jul; 47 (7 Suppl. 1): S104-8
136. Marshall DA, Hux M. Design and analysis issues for economic analysis alongside clinical trials. Med Care 2009 Jul; 47 (7 Suppl. 1): S14-20
137. Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008 Nov; 63 (11): 962-7
138. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007 Apr 17; 146 (8): 545-55 (Pubitemid 351650535)
139. Celli BR. Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. Proc Am Thorac Soc 2006; 3 (1): 58-65